XML 62 R20.htm IDEA: XBRL DOCUMENT v3.3.0.814
Significant Accounting Policies, Revenue Recognition (Details)
1 Months Ended 3 Months Ended 9 Months Ended
Sep. 30, 2013
USD ($)
Dec. 31, 2012
USD ($)
Target
Jun. 30, 2012
USD ($)
Jan. 31, 2012
USD ($)
Sep. 30, 2015
USD ($)
Jun. 30, 2015
USD ($)
Sep. 30, 2014
USD ($)
Mar. 31, 2014
USD ($)
Sep. 30, 2015
USD ($)
AccountingUnit
Agreement
Category
Stage
Sep. 30, 2014
USD ($)
Revenue Recognition [Abstract]                    
Licensing and royalty revenue         $ 203,000   $ 265,000   $ 1,664,000 $ 9,325,000
Collaborations and Licensing Agreements [Member]                    
Revenue Recognition [Abstract]                    
Number of categories of milestone events | Category                 3  
Number of stages of life-cycle of drugs | Stage                 3  
Collaborations and Licensing Agreements [Member] | Development Milestones - New Development Candidate [Member] | Minimum [Member]                    
Revenue Recognition [Abstract]                    
Completion period                 12 months  
Collaborations and Licensing Agreements [Member] | Development Milestones - New Development Candidate [Member] | Maximum [Member]                    
Revenue Recognition [Abstract]                    
Completion period                 18 months  
Collaborations and Licensing Agreements [Member] | Development Milestones - Phase 1 [Member] | Minimum [Member]                    
Revenue Recognition [Abstract]                    
Completion period                 1 year  
Collaborations and Licensing Agreements [Member] | Development Milestones - Phase 1 [Member] | Maximum [Member]                    
Revenue Recognition [Abstract]                    
Completion period                 2 years  
Collaborations and Licensing Agreements [Member] | Development Milestones - Phase 2 [Member] | Minimum [Member]                    
Revenue Recognition [Abstract]                    
Completion period                 1 year  
Collaborations and Licensing Agreements [Member] | Development Milestones - Phase 2 [Member] | Maximum [Member]                    
Revenue Recognition [Abstract]                    
Completion period                 3 years  
Collaborations and Licensing Agreements [Member] | Development Milestones - Phase 3 [Member] | Minimum [Member]                    
Revenue Recognition [Abstract]                    
Completion period                 2 years  
Collaborations and Licensing Agreements [Member] | Development Milestones - Phase 3 [Member] | Maximum [Member]                    
Revenue Recognition [Abstract]                    
Completion period                 4 years  
Collaborations and Licensing Agreements [Member] | Regulatory Milestones [Member] | Minimum [Member]                    
Revenue Recognition [Abstract]                    
Time to prepare and submit regulatory filings                 6 months  
Time to obtain approval                 1 year  
Collaborations and Licensing Agreements [Member] | Regulatory Milestones [Member] | Maximum [Member]                    
Revenue Recognition [Abstract]                    
Time to prepare and submit regulatory filings                 12 months  
Time to obtain approval                 2 years  
Collaborations and Licensing Agreements [Member] | Commercialization Milestones [Member]                    
Revenue Recognition [Abstract]                    
Pre-specified sales threshold                 $ 1,000,000,000  
Bayer HealthCare [Member] | Agreement Entered into in May 2015 [Member]                    
Revenue Recognition [Abstract]                    
Upfront fee received           $ 100,000,000        
Number of units of accounting | AccountingUnit                 3  
Bayer HealthCare [Member] | Agreement Entered into in May 2015 [Member] | ISIS-FXI [Member]                    
Revenue Recognition [Abstract]                    
Upfront fee recognized           $ 91,200,000        
Assumed percentage change in estimated selling price           10.00%        
Percentage change in earned revenue based on assumed change in estimated selling price           1.00%        
Change in earned revenue based on assumed change in estimated selling price           $ 900,000        
Bayer HealthCare [Member] | Agreement Entered into in May 2015 [Member] | ISIS-FXI Development Services [Member]                    
Revenue Recognition [Abstract]                    
Upfront fee recorded as deferred revenue           4,300,000        
Bayer HealthCare [Member] | Agreement Entered into in May 2015 [Member] | ISIS-FXI API [Member]                    
Revenue Recognition [Abstract]                    
Upfront fee recorded as deferred revenue           $ 4,500,000        
Biogen Idec [Member] | Collaborations and Licensing Agreements [Member]                    
Revenue Recognition [Abstract]                    
Number of collaboration agreements | Agreement                 4  
Biogen Idec [Member] | Agreement Entered into in January 2012 [Member] | Nusinersen [Member]                    
Revenue Recognition [Abstract]                    
Upfront fee recorded as deferred revenue       $ 29,000,000            
Biogen Idec [Member] | Agreement Entered into in June 2012 [Member] | ISIS-DMPK [Member]                    
Revenue Recognition [Abstract]                    
Upfront fee recorded as deferred revenue     $ 12,000,000              
Biogen Idec [Member] | Agreement Entered into in December 2012 [Member] | Neurology [Member]                    
Revenue Recognition [Abstract]                    
Upfront fee recorded as deferred revenue   $ 30,000,000                
Number of targets | Target   3                
Biogen Idec [Member] | Agreement Entered into in September 2013 [Member] | Strategic Neurology [Member]                    
Revenue Recognition [Abstract]                    
Upfront fee recorded as deferred revenue $ 100,000,000                  
Term of collaboration agreement                 6 years  
Alnylam [Member]                    
Revenue Recognition [Abstract]                    
Licensing and royalty revenue               $ 7,700,000